{"id":827971,"date":"2025-03-20T08:10:42","date_gmt":"2025-03-20T12:10:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-significantly-outperforms-standard-of-care-in-first-line-egfr-mutated-lung-cancer-with-compelling-new-data-at-elcc-2025\/"},"modified":"2025-03-20T08:10:42","modified_gmt":"2025-03-20T12:10:42","slug":"rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-significantly-outperforms-standard-of-care-in-first-line-egfr-mutated-lung-cancer-with-compelling-new-data-at-elcc-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-significantly-outperforms-standard-of-care-in-first-line-egfr-mutated-lung-cancer-with-compelling-new-data-at-elcc-2025\/","title":{"rendered":"RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib <\/i>\n <\/p>\n

\n Preventative dermatologic regimen meets primary endpoint and enhances patient experience<\/i>\n <\/p>\n

\n
\n RARITAN, N.J.<\/span>
\n <\/span>, March 20, 2025<\/span><\/span> \/PRNewswire\/ — Johnson & Johnson (NYSE:JNJ)\u00a0announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT\u00ae<\/sup> (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR<\/i>) exon 19 deletions (ex19del) or L858R substitution mutations.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Johnson
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Patients with EGFR<\/i>-mutated non-small cell lung cancer deserve to live longer and with more hope than current treatments provide,” said Yusri Elsayed<\/span>, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology,\u00a0Johnson & Johnson\u00a0Innovative Medicine. “These newest and compelling overall survival data for first-line treatment with RYBREVANT and LAZCLUZE are fundamentally changing treatment discussions and transforming expectations for how long patients can live.”<\/p>\n

Additional presentations will feature the first data from the Phase 2 COCOON study, evaluating a simple to use and widely accessible dermatologic regimen given prophylactically to\u00a0patients receiving the RYBREVANT\u00ae <\/sup>combination, and new results from the Phase 2 PALOMA-2 study evaluating the feasibility of switching to subcutaneous (SC) amivantamab.<\/p>\n

“We are redefining the way EGFR<\/i>-mutated non-small cell lung cancer is treated with therapies that improve survival and give patients more time,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Lead, Oncology,\u00a0Johnson & Johnson\u00a0Innovative Medicine. “The chemotherapy-free regimen of RYBREVANT plus LAZCLUZE represents a major breakthrough, offering an innovative and life-extending option that can meaningfully impact lives.”<\/p>\n

ELCC 2025 Presentation Highlights:<\/p>\n